Plain-English translation of NCT06997081 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications — , , and — for people newly diagnosed with multiple myeloma, a cancer of blood cells in the bone marrow. The goal is to see how well this medication combination works and whether it can help patients achieve a special state where cancer cells become undetectable in the bone marrow. Researchers want to understand if this treatment is more effective than standard options available today.
Multiple myeloma is a serious blood cancer that currently requires long-term treatment. This trial exists because is a newer type of drug that works differently than older treatments, and doctors want to know if combining it with other proven medications might help patients live longer and healthier lives.
You likely qualify if…
You likely don't qualify if…
You would receive the three-drug combination as part of your standard cancer care over about 2.5 years. This involves taking medications (some by mouth, some by injection or infusion) on a regular schedule, with frequent visits to the research center for blood tests, bone marrow samples, and imaging scans to monitor how well the treatment is working. The study team will track how your myeloma responds and watch for any side effects throughout your participation.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Miami
Collaborators
Pfizer
Enrollment target
~104 participants
Started
September 2025
Primary completion
September 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Carl O Landgren, MD
Professor of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.